Sep 3, 2025 04:05PM Longeveron appoints Than Powell as interim CEO, Joshua Hare as chairman

Jul 21, 2025 09:15AM Longeveron licenses stem cell patent from University of Miami

Jul 8, 2025 09:15AM Longeveron gets FDA approval for pediatric heart disease trial

Jun 26, 2025 09:05AM Longeveron (LGVN) Appoints Than Powell as Chief Business Officer

Jun 24, 2025 06:31AM Longeveron (LGVN) Completes Enrollment of Pivotal Phase 2b Trial of Laromestrocel

Mar 20, 2025 09:00AM Longeveron (LGVN) Announces Positive Type B Meeting with U.S. FDA Regarding Pathway to BLA for Laromestrocel in Alzheimer’s Disease

Mar 11, 2025 08:31AM Longeveron (LGVN) Announces Nature Medicine Publication of Results of Phase 2a Clinical Trial Evaluating Laromestrocel in Alzheimer’s Disease

Feb 28, 2025 04:04PM Longeveron (LGVN) Reports FY24 Results, Provides Business Update

Feb 18, 2025 09:26AM Longeveron (LGVN) Announces WHO Approval of “laromestrocel”

Nov 11, 2024 09:06AM Longeveron (LGVN) Appoints Devin Blass as CTO

Oct 29, 2024 10:03AM Longeveron (LGVN) Presents Lomecel-B Data for Alzheimer’s Disease Indication

Sep 3, 2024 09:02AM Longeveron (LGVN) Announces Positive Type C Meeting with FDA Regarding Pathway to BLA for Lomecel-B

Jul 18, 2024 08:45AM Longeveron (LGVN) Announces 2.24M Share Offering at $4.025/sh

Jul 17, 2024 08:01AM Longeveron (LGVN) Granted FDA Fast Track Designation for Lomecel-B

Jul 10, 2024 07:31AM Longeveron (LGVN) Granted FDA Regenerative Medicine Advanced Therapy Designation for Lomecel-B

Jul 9, 2024 09:01AM Longeveron (LGVN) Appoints Neha Motwani to its Board

Jun 17, 2024 08:39AM Longeveron (LGVN) Exercises $4.4M Worth of Warrants

Jun 11, 2024 09:01AM Longeveron (LGVN) Announces Completion of Successful Investigator Meeting for On-going Phase 2b Clinical Trial Evaluating Lomecel-B as a Potential Treatment for HLHS